These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30857817)

  • 21. Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.
    Brixner DI; Ye X; Chu TC; Blumentals WA; Hassanein TI
    Am J Health Syst Pharm; 2009 Dec; 66(24):2171-8. PubMed ID: 19966085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
    Schulze Zur Wiesch J; Pudelski N; Hoepner L; Supplieth M; Buggisch P; Lohse AW; Lüth S
    Hepatology; 2011 Apr; 53(4):1405-6; author reply 1407. PubMed ID: 21480360
    [No Abstract]   [Full Text] [Related]  

  • 23. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 24. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
    Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
    J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of chronic hepatitis C: efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients].
    Lee YJ
    Korean J Hepatol; 2008 Dec; 14(4):443-5. PubMed ID: 19119239
    [No Abstract]   [Full Text] [Related]  

  • 26. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
    Bruno R; Sacchi P; Maiocchi L; Zocchetti C; Ciappina V; Patruno S; Filice G
    Antivir Ther; 2005; 10(2):201-5. PubMed ID: 15865213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
    Perrillo R; Rothstein KD; Rubin R; Alam I; Imperial J; Harb G; Hu S; Klaskala W
    J Viral Hepat; 2004 Mar; 11(2):157-65. PubMed ID: 14996351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
    Kim JI; Kim SH; Lee BS; Lee HY; Lee TH; Kang YW; Lee HIe; Kim AN; Nam SW; Park BC; Chae HB; Kim SB; Song IH; Park JY; Kim HS
    Korean J Hepatol; 2008 Dec; 14(4):493-502. PubMed ID: 19119244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
    Boulestin A; Kamar N; Legrand-Abravanel F; Sandres-Saune K; Alric L; Vinel JP; Rostaing L; Izopet J
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3610-2. PubMed ID: 15328140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
    Wang LJ; Chen SW; Chen CK; Yen CL; Chang JJ; Lee TS; Liu CJ; Chen LW; Chien RN
    BMC Psychiatry; 2016 Nov; 16(1):424. PubMed ID: 27884134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
    Neri S; Pulvirenti D; Bertino G
    Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.
    Katano Y; Kumada T; Nakano I; Toyoda H; Ishigami M; Hayashi K; Honda T; Goto H
    Hepatogastroenterology; 2009; 56(90):485-91. PubMed ID: 19579626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.